Status:
RECRUITING
SPY003-207 in Healthy Volunteers
Lead Sponsor:
Spyre Therapeutics, Inc.
Collaborating Sponsors:
Altasciences Company Inc.
Conditions:
Healthy
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single dose, first in human safety, tolerability, and pharmacokinetic study of SPY003-207 in healthy participants.
Eligibility Criteria
Inclusion
- Healthy men and women
- Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits
Exclusion
- Participation in more than one cohort
- Evidence of clinically significant abnormality or disease
- Known history of illicit drug use or drug abuse, harmful alcohol use or alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study drug
- History of severe allergic reactions or hypersensitivity
- Donation or loss of \>1 unit of whole blood within 1 month prior to dosing
Key Trial Info
Start Date :
March 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT06873724
Start Date
March 10 2025
End Date
December 1 2026
Last Update
June 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Spyre Site 1
Montreal, Quebec, Canada, H3P 3P1